Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MITO Stealth BioTherapeutics (MITO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Stealth BioTherapeutics Stock (NASDAQ:MITO) 30 days 90 days 365 days Advanced Chart Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get MITO alerts:Sign Up Key Stats Today's Range$0.32▼$0.3250-Day Range$0.31▼$0.3252-Week Range$0.16▼$1.03VolumeN/AAverage Volume946,105 shsMarket Capitalization$23.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewStealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.Read More… JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Receive MITO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stealth BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MITO Stock News HeadlinesFDA AdCom votes in favour of Stealth’s Barth syndrome drugOctober 12, 2024 | msn.comSTEALTH BIOTHERAPEUTICS' BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATIONMay 7, 2024 | prnewswire.com“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…November 21, 2024 | Colonial Metals (Ad)Stealth BioTherapeutics to Present at JMP Citizens Life Sciences ConferenceMay 6, 2024 | prnewswire.comBolt Biotherapeutics IncApril 17, 2024 | money.usnews.comSTEALTH BIOTHERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROMEApril 8, 2024 | prnewswire.comSonnet BioTherapeutics Holdings Inc.February 22, 2024 | wsj.comIovance Biotherapeutics Inc (IOVA)February 9, 2024 | investing.comSee More Headlines MITO Stock Analysis - Frequently Asked Questions How were Stealth BioTherapeutics' earnings last quarter? Stealth BioTherapeutics Corp (NASDAQ:MITO) posted its quarterly earnings results on Thursday, August, 5th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.01. When did Stealth BioTherapeutics IPO? Stealth BioTherapeutics (MITO) raised $81 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 6,200,000 shares at $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets acted as the underwriters for the IPO and Nomura was co-manager. What other stocks do shareholders of Stealth BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stealth BioTherapeutics investors own include Tesla (TSLA), TherapeuticsMD (TXMD), NIO (NIO), Plug Power (PLUG), Allena Pharmaceuticals (ALNA), SCYNEXIS (SCYX) and Tonix Pharmaceuticals (TNXP). Company Calendar Last Earnings8/05/2021Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MITO CUSIPN/A CIK1696396 Webwww.stealthbt.com Phone617-600-6888FaxN/AEmployees29Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,530,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-142.81% Debt Debt-to-Equity RatioN/A Current Ratio3.68 Quick Ratio3.68 Sales & Book Value Annual Sales$21.09 million Price / Sales1.12 Cash FlowN/A Price / Cash FlowN/A Book Value($0.79) per share Price / Book-0.41Miscellaneous Outstanding Shares73,552,000Free FloatN/AMarket Cap$23.54 million OptionableNot Optionable Beta1.46 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:MITO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stealth BioTherapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Stealth BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.